pembrolizumab
merck
['pembro', 'bcsm']
keynote-522 exploratory analysis of efs within residual cancer burden (rcb) categories: benefit of pembrolizumab was seen in rcb-0, -1, and -2 but not seen in small group with rcb-3. distant recurrence most common event. lajos pusztai of #asco22 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.